CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that Chairman and Chief Executive Officer Henri A. Termeer will present at the 27th Annual JPMorgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco. Mr. Termeer will provide an overview of the company and describe Genzyme’s strategy to deliver sustainable growth through 2011 and beyond. The presentation will take place on Tuesday, January 13, 2009, at 9:00 a.m. (PST).
To listen to the presentation, please visit the Investor Events section of www.genzyme.com.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
Genzyme’s press releases and other company information are available at www.genzyme.com and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.
Genzyme® is registered trademark of Genzyme or its subsidiaries. All rights reserved.
Erin Emlock, 617-768-6923
Patrick Flanigan, 617-768-6563